About OrbusNeich
OrbusNeich is a company based in Hong Kong (China) founded in 2005. OrbusNeich has completed 2 acquisitions, including Eucatech and Revass Utama Medika. OrbusNeich operates in a competitive market with competitors including Silk Road Medical, HDL Therapeutics, Lifetech Scientific Corporation, Supira Medical and Shanghai Baixin'an Biotechnology, among others.
- Headquarter Hong Kong, China
- Stage Public
- SectorsHealthcare
- Website orbusneich.com
- Social LinkedIn X
- Legal Name Orbusneich Medical Group Holdings Limited
- Annual Revenue₹2.2 Lakh
FY 2022 · -90% YoY
- Net Profit₹81,408
FY 2022 · 36% margin
- EBITDA₹1.2 Lakh
FY 2022 · 52% margin
- Investments & AcquisitionsEucatech
& 1 more
Associated legal entities of OrbusNeich
OrbusNeich operates through Orbusneich Medical (India) Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Orbusneich Medical (India) Private Limited CIN U33110MH2009PTC190834 | Strike Off | 09 Mar 2009 | Mumbai, Maharashtra | ₹0.0 Cr | – | 2 | View details |
Board of directors of Orbusneich Medical (India) Private Limited (OrbusNeich)
Orbusneich Medical (India) Private Limited is the primary company behind OrbusNeich. The board of Orbusneich Medical (India) Private Limited currently have 2 directors; the longest-serving is Saarthak Mehta, appointed in 2017. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saarthak Mehta DIN 07840983 | Director | 26 Jun 2017 | 9 yrs 3 mo | Orbusneich Medical (India) Private Limited |
| Wing Shing Chen DIN 08101198 | Director | 18 Apr 2018 | 8 yrs 5 mo | Orbusneich Medical (India) Private Limited |
People of OrbusNeich
22 people are tracked at OrbusNeich (11 in leadership, 1 in board & advisors, 10 in team).
| Name | Role | Group |
|---|---|---|
Alain Djamel Khair | Chief Commercial Officer | Leadership |
David Chien | Chairman, Executive Director and Chief Executive Officer | Leadership |
Maisy Leung | Director, Global Supply Chain | Leadership |
Ken Choen Yip | Financial Director | Leadership |
Denise Lau | Executive Director And Chief Operating Officer | Leadership |
Eva Chan | Director, Human Resources | Leadership |
Jason Chen | Executive Director And Chief Financial Officer | Leadership |
Oliver J. | Senior Director Sales, North & West Europe | Leadership |
Michael Bernard | Sales Director | Leadership |
Ricky Kwan | Vice President Sales | Leadership |
Eric Dong | VP, Manufacturing | Leadership |
Yi Zhou | Non-executive Director | Board & advisors |
Vijay Jalanilla | Supply Chain Manager | Team |
Marcel van Putten | Human Resources Officer | Team |
Marianne Bakker | HR Manager | Team |
Dennis Liong | Operations Manager (ft. Lauderdale) | Team |
Christie Long | Country Manager | Team |
Ricardo Fernandes Henriques | Clinical Sales Rep | Team |
Ralf von Seelen | Sales Agent Interventional Cardiology/angiology/radiology/vascular Surgery | Team |
Tysus Kok | Senior Manager, Sales & Marketing – Endovascular, APAC | Team |
2 more people are available in the full profile.
Complete people profiles for OrbusNeich
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OrbusNeich
OrbusNeich is a publicly listed company on the HKEX with ticker symbol 6929 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Dec 2022
- Listed onHKG: 6929
- Listed entityOrbusNeich Medical Group Holdings Limited
- Exchange sectorHealth technology
- ISINKYG6773B1005
- Share price3.81 HKD (-0.39% on the day) · 2026-10-12
- Market capitalisation3,146,964,861.00 HKD
- Price to earnings9.2
- EPS (diluted, trailing year)0.41 HKD
- Dividend yield5.24%
- Volume (last session)91,000
Financials of OrbusNeich
Figures of Orbusneich Medical (India) Private Limited, the primary company behind OrbusNeich, for FY 2022. Revenue was ₹2.2 Lakh (-90% year on year). Net profit was ₹81,408 (36% margin). EBITDA was ₹1.2 Lakh (52% margin). Revenue has grown at a compounded annual rate of -49% over three years and -19% over five years.
- ₹2.2 LakhRevenue · FY 2022 · -90% YoY
- ₹81,408Net profit · 36% margin
- ₹1.2 LakhEBITDA · 52% margin
- ₹1 LakhPaid-up capital
- -49%Revenue CAGR, 3 years
- -19%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.41B HKD | 326.6M HKD | 349.8M HKD |
| 2024 | 1.28B HKD | 309.9M HKD | 309.6M HKD |
| 2023 | 1.20B HKD | 352.9M HKD | 324.4M HKD |
| 2022 | 1.07B HKD | 144.8M HKD | 258.4M HKD |
| 2021 | 905.2M HKD | -34.5M HKD | 215.6M HKD |
Balance sheet, profit and loss, cash flow and ratios of Orbusneich Medical (India) Private Limited are on its company page.
Detailed financial statements for OrbusNeich
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OrbusNeich
OrbusNeich has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Eucatech and Revass Utama Medika.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Leading medical device distributor in Indonesia, providing innovative solutions | revassutamamedika.com | Jakarta, Indonesia | 2010 | Nov 2023 | $15.12M | |
Products are developed for cardiovascular and endovascular procedures. | eucatech.de | – | 1997 | Nov 2023 | •••• |
Complete acquisition details for OrbusNeich
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OrbusNeich
4 dated milestones of OrbusNeich across 18 years, from founding to its latest funding, stage changes and deals.
- Founded OrbusNeich is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Eucatech.
- Acquisition Acquires Revass Utama Medika.
Competitors of OrbusNeich
OrbusNeich operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Silk Road Medical, HDL Therapeutics, Lifetech Scientific Corporation, Supira Medical and Shanghai Baixin'an Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| silkroadmed.com | 2007 | Sunnyvale, United States | $241.8M | 352 | Provider of neuroprotection devices for carotid artery disease | |
| hdltherapeutics.com | 2010 | Short Hills, United States | $17.79M | – | Therapy to reverse coronary atherosclerosis is developed using patient plasma. | |
| lifetechmed.com | 1999 | Shenzhen, China | $66.2M | 44 | Interventional devices for cardiovascular and vascular diseases are developed. | |
| supiramedical.com | 2016 | Campbell, United States | $240.5M | – | Developer of ventricular assist devices for coronary intervention and cardiogenic shock | |
| bio-heart.com | 2014 | Pudong, China | $15.79M | – | A bioabsorbable coronary rapamycin-eluting stent system is developed using PLLA. | |
| avspulse.com | 2017 | Ann Arbor, United States | $70.45M | – | Pulsatile intravascular lithotripsy is developed for calcified arterial disease treatment. | |
| s4medical.com | 2017 | Columbus, United States | $7.62M | – | Catheter ablation treatments for atrial fibrillation are developed. | |
| protaryx.com | 2019 | Baltimore, United States | $5.1M | – | Protaryx Medical is focused on developing transseptal access devices. | |
| transvascular.com | 1996 | Menlo Park, United States | $10.8M | – | A TransAccess Catheter System that is used to deliver cells to damaged portions of the heart | |
| medinol.com | 1992 | Tel Aviv, Israel | – | – | Thin cobalt-chrome stents are developed for coronary cardiovascular treatment. |
Detailed competitors of OrbusNeich
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OrbusNeich
The website of OrbusNeich (orbusneich.com) receives about 9K visits a month.
- Monthly visits9K
▲ 25.6% vs previous month
Websites whose visitors overlap most with OrbusNeich. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
medicaldevicedaily.com | medicaldevicedaily.com | 100% | – | – | – |
multiplate.net | multiplate.net | 90% | – | – | – |
| medpagetoday.com | 83% | 1.5M | #46,019 | View details | |
| sirnaomics.com | 83% | 1.9K | #8,322,653 | View details | |
inate.org | inate.org | 57% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for OrbusNeich
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Orbusneich
Complete news archive for OrbusNeich
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OrbusNeich
10 companies that operate in the same segment as OrbusNeich (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OrbusNeich
OrbusNeich was founded in 2005.
OrbusNeich is headquartered in Hong Kong, China.
The primary company behind OrbusNeich, Orbusneich Medical (India) Private Limited, reported revenue of ₹2.2 Lakh for FY 2022, down 90% year on year.
OrbusNeich develops devices for the treatment of vascular diseases. Their product portfolio includes COMBO dual therapy stent, Genous bio-engineered cobalt chromium stent, Azule cobalt chromium stent, Sapphire II PRO semi-compliant balloon, Sapphire ll NC non-compliant balloon, Scoreflex force dilatation balloon.
OrbusNeich's top competitors include Silk Road Medical, Lifetech Scientific Corporation and Supira Medical.
Yes, OrbusNeich is publicly traded on HKEX under the ticker symbol 6929.
OrbusNeich has made 2 acquisitions, including Eucatech, and Revass Utama Medika.
OrbusNeich operates through Orbusneich Medical (India) Private Limited.
The legal entities of OrbusNeich currently have 2 directors, including Saarthak Mehta, Wing Shing Chen.